---
pmid: '34348115'
title: Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose
  tolerance and hepatic steatosis.
authors:
- Jiang Z
- Zhao M
- Voilquin L
- Jung Y
- Aikio MA
- Sahai T
- Dou FY
- Roche AM
- Carcamo-Orive I
- Knowles JW
- Wabitsch M
- Appel EA
- Maikawa CL
- Camporez JP
- Shulman GI
- Tsai L
- Rosen ED
- Gardner CD
- Spiegelman BM
- Svensson KJ
journal: Cell Metab
year: '2021'
full_text_available: false
pmcid: PMC8429235
doi: 10.1016/j.cmet.2021.07.010
---

# Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis.
**Authors:** Jiang Z, Zhao M, Voilquin L, Jung Y, Aikio MA, Sahai T, Dou FY, Roche AM, Carcamo-Orive I, Knowles JW, Wabitsch M, Appel EA, Maikawa CL, Camporez JP, Shulman GI, Tsai L, Rosen ED, Gardner CD, Spiegelman BM, Svensson KJ
**Journal:** Cell Metab (2021)
**DOI:** [10.1016/j.cmet.2021.07.010](https://doi.org/10.1016/j.cmet.2021.07.010)
**PMC:** [PMC8429235](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429235/)

## Abstract

1. Cell Metab. 2021 Sep 7;33(9):1836-1852.e11. doi: 10.1016/j.cmet.2021.07.010. 
Epub 2021 Aug 3.

Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose 
tolerance and hepatic steatosis.

Jiang Z(1), Zhao M(1), Voilquin L(1), Jung Y(1), Aikio MA(2), Sahai T(1), Dou 
FY(2), Roche AM(2), Carcamo-Orive I(3), Knowles JW(4), Wabitsch M(5), Appel 
EA(6), Maikawa CL(7), Camporez JP(8), Shulman GI(9), Tsai L(10), Rosen ED(10), 
Gardner CD(11), Spiegelman BM(2), Svensson KJ(12).

Author information:
(1)Department of Pathology, Stanford University School of Medicine, Stanford, CA 
94305, USA; Stanford Diabetes Research Center, Stanford University School of 
Medicine, Stanford, CA 94305, USA.
(2)Department of Cell Biology, Harvard Medical School and Department of Cancer 
Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
(3)Stanford Diabetes Research Center, Stanford University School of Medicine, 
Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular 
Medicine, and Cardiovascular Institute, Stanford University School of Medicine, 
Stanford, CA 94305, USA.
(4)Stanford Diabetes Research Center, Stanford University School of Medicine, 
Stanford, CA 94305, USA; Department of Medicine, Division of Cardiovascular 
Medicine, and Cardiovascular Institute, Stanford University School of Medicine, 
Stanford, CA 94305, USA; Stanford Prevention Research Center, Stanford 
University, Stanford, CA 94305, USA.
(5)Division of Pediatric Endocrinology and Diabetes, University Medical Center 
Ulm, Ulm, Germany.
(6)Stanford Diabetes Research Center, Stanford University School of Medicine, 
Stanford, CA 94305, USA; Department of Bioengineering, Stanford University, 
Stanford, CA 94305, USA; Department of Materials Science & Engineering, Stanford 
University, Stanford, CA 94305, USA; Department of Pediatrics (Endocrinology), 
Stanford University, Stanford, CA 94305, USA.
(7)Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
(8)Department of Physiology, Ribeirao Preto School of Medicine, University of 
Sao Paulo, Sao Paulo, Brazil; Department of Internal Medicine, Yale University 
School of Medicine, New Haven, CT 06519, USA.
(9)Department of Internal Medicine, Yale University School of Medicine, New 
Haven, CT 06519, USA; Department of Cellular and Molecular Physiology and Howard 
Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 
06519, USA.
(10)Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
(11)Stanford University, Stanford, CA 94305, USA.
(12)Department of Pathology, Stanford University School of Medicine, Stanford, 
CA 94305, USA; Stanford Diabetes Research Center, Stanford University School of 
Medicine, Stanford, CA 94305, USA. Electronic address: katrinjs@stanford.edu.

Comment in
    Nat Rev Endocrinol. 2021 Dec;17(12):709-710. doi: 
10.1038/s41574-021-00569-z.

With the increasing prevalence of type 2 diabetes and fatty liver disease, there 
is still an unmet need to better treat hyperglycemia and hyperlipidemia. Here, 
we identify isthmin-1 (Ism1) as an adipokine and one that has a dual role in 
increasing adipose glucose uptake while suppressing hepatic lipid synthesis. 
Ism1 ablation results in impaired glucose tolerance, reduced adipose glucose 
uptake, and reduced insulin sensitivity, demonstrating an endogenous function 
for Ism1 in glucose regulation. Mechanistically, Ism1 activates a PI3K-AKT 
signaling pathway independently of the insulin and insulin-like growth factor 
receptors. Notably, while the glucoregulatory function is shared with insulin, 
Ism1 counteracts lipid accumulation in the liver by switching hepatocytes from a 
lipogenic to a protein synthesis state. Furthermore, therapeutic dosing of 
recombinant Ism1 improves diabetes in diet-induced obese mice and ameliorates 
hepatic steatosis in a diet-induced fatty liver mouse model. These findings 
uncover an unexpected, bioactive protein hormone that might have simultaneous 
therapeutic potential for diabetes and fatty liver disease.

Copyright Â© 2021 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.cmet.2021.07.010
PMCID: PMC8429235
PMID: 34348115 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of interests The authors declare no 
competing interests.
